Mark manfredi ikenaoncology.com
WebMark Manfredi President & Chief Executive Officer Phone Email See Profile Key Employees of Ikena Oncology Jotin Marango Chief Financial Officer & Head of Corporate Develo... Phone Email Sergio Santillana Chief Medical Officer Phone Email Search Full List of Executives Index of contact profiles from Ikena Oncology 1-25 of 80 results WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding …
Mark manfredi ikenaoncology.com
Did you know?
Web28 feb. 2024 · Presenter: Mark Manfredi, Ph.D., Chief Executive Officer of Ikena Oncology Date: Tuesday, March 7, 2024 Time: 2:10pm-3:10pm EST Webcast Link: Targeted Oncology Panel The webcast link will stream the live panel and will be archived for 30 days following the end of the conference, accessible above. Web12 apr. 2024 · Their IKNA share price forecasts range from $13.00 to $22.00. On average, they expect the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 322.7% from the stock's current price. View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts.
WebShared by Mark Manfredi. Proud of the Ikena Oncology team for their innovative work on this program. The promise of MEK as a target has … Web5 jan. 2024 · January 05, 2024 07:00 AM Eastern Standard Time. BOSTON-- ( BUSINESS WIRE )--Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed ...
Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops programs across distinct molecular targets and biologic pathways modulating both the immune system and the tumor. Type Public Status Active Founded 2016 HQ Boston, … WebSee the company profile for Ikena Oncology, Inc. (IKNA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation.
Web10 nov. 2024 · Ikena’s pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.comwww.ikenaoncology.comor follow us on Twitterand LinkedIn. …
player stats ark iniWeb8 jul. 2024 · BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation ... primary school in woodlandsWeb20 uur geleden · 8,517 followers. 1y. Our president and CEO Mark Manfredi, Ph.D., discussed Ikena’s unique corporate culture and goal to create a vibrant, innovative environment for employees to feel supported ... primary school in zurichWeb6 sep. 2024 · BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... player stats arizona cardinalsWebIkena Oncology Profile and History . Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients who need life-saving treatment, by understanding what drives their disease. primary school in yishunWeb10 apr. 2024 · Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. About the company Rewards Revenue is forecast to grow 19.97% per year Risk Analysis Earnings are forecast to decline by an average of 16.8% per year for the next 3 … player stats 2 modWeb6 apr. 2024 · Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling … player stats memphis redbirds 2022